NCT02753504

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

A Dose-block Randomized, Double-blind, Placebo-controlled, Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519

Detailed description

A Dose-block Randomized, Double-blind, Placebo-controlled, Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	CKD-519
DRUG	placebo

Timeline

• Start date: 2016-04-01
• Primary completion: 2016-07-01
• Completion: 2016-07-01
• First posted: 2016-04-28
• Last updated: 2017-07-13

Locations

1 site across 1 country: South Korea